The Ensuring Patient Access to Critical Breakthrough Products Act

The bipartisan bill, The Ensuring Patient Access to Critical Breakthrough Products Act, would require Medicare to cover all breakthrough devices after approval from FDA for four years. After four years, the Centers for Medicare & Medicaid Services (CMS) would determine whether coverage should be permanent. Read the article here…

Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link’s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org